Travere therapeutics and csl vifor announce sparsentan receives positive chmp opinion for the treatment of iga nephropathy

Committee for medicinal products for human use (chmp) recommends approval of the conditional marketing authorization (cma) for sparsentan for the treatment of iga nephropathy (igan) in europe
TVTX Ratings Summary
TVTX Quant Ranking